Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iMSC for Prevention of Acute Graft-versus-host Disease After Allogeneic HSCT
NCT06949267Phase 1Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jun 2025
- Primary completion
- Sep 2026
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
01
Overview
Phase 1, randomised, open-label trial of iMSC in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Cumulative incidence of degree III-IV acute Graft-versus-Host Disease at 100 days. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
iMSC
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT06949267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06949267.